Sutro Biopharma Announces Oral Presentation at ASCO 2023 : c

- Consistent with data shared in January 2023, the presentation at ASCO 2023 highlights data from the Phase 1 dose-expansion study for luveltamab...

Related Keywords

United States , Hebron , Israel General , Israel , Chicago , Illinois , Canada , Barcelona , Comunidad Autonoma De Cataluna , Spain , American , Astellas Pharma , Anne Borgman , Anniej Chang , Sutro Biopharma , Bristol Myers Squibb , Luveltamab Tazevibulin , Amy Bonanno , Exchange Commission , Hebron Institute Of Oncology , Solebury Strategic Communications , Sutro Biopharma Inc , American Society Of Clinical Oncology , Hebron University Hospital , Clinical Oncology , Annual Meeting , Principal Investigator , Ana Oaknin , Gynecological Tumor Unit , Attending Physician , Principal Clinical Investigator , Gynecological Malignancies Group , Hebron Institute , Tumor Proportion Score , Chief Medical , South San Francisco , Private Securities Litigation Reform Act , Fast Track , Nasdaq Stro , Nc ,